---
company: Amphastar Pharmaceuticals, Inc.
ticker: AMPH
form: 8-K
filed: 2026-05-07
accession: 0001297184-26-000031
source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/
---

# Amphastar Pharmaceuticals (AMPH) earnings release, May 7, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) · Form 8-K, Item 2.02 · Filed 2026-05-07 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/)

​

Amphastar Pharmaceuticals

Reports Financial Results for the Three Months Ended

March 31, 2026

​

​

​

​

​

RANCHO CUCAMONGA, CA – May 7, 2026 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026.

​

“In the first quarter of 2026, we continued to strengthen our commercial foundation and core business, highlighted by the approval and subsequent launch of Ipratropium Bromide HFA, while also making meaningful advancements across our pipeline that will support our long‑term strategy,” said Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer. “To begin the year, we broadened our portfolio through an exclusive license agreement for a fully synthetic corticotropin compound. At the same time, we remain committed to investing in our proprietary pipeline and capabilities, which we believe will support sustainable long-term growth.”

​

*

Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled “Non-GAAP Financial Measures” and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

​

First Quarter Results

​

​

​

​

Changes in net revenues as compared to the first quarter of the prior year were primarily driven by:

​

​

​

Changes in the cost of revenues and gross margin were primarily driven by:

​

​

​

​

​

​

​

​

The change in non-operating expenses, net, is primarily a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the three months ended March 31, 2026.

​

Cash flow provided by operating activities for the three months ended March 31, 2026, was $47.8 million.

​

Pipeline Information

​

The Company currently has one abbreviated new drug application (“ANDA”) and one biosimilar insulin candidate filed with the FDA targeting products with a combined market size exceeding $1.6 billion, along with two biosimilar products in development targeting products with a market size exceeding $3.7 billion, and two generic products in development targeting products with a market size of over $0.8 billion. This market information is based on IQVIA data for the 12 months ended March 31, 2026. The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms.

​

The Company’s proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions.

​

Conference Call Information

​

The Company will hold a conference call to discuss its financial results today, May 7, 2026, at 2:00 p.m. Pacific Time.

​

To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.

​

The call can also be accessed on the Investors page on the Company’s website, www.amphastar.com.

​

Non-GAAP Financial Measures

​

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance because the Company’s management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation

​

​ of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

​

Market Data

​

This press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections.

​

About Amphastar Pharmaceuticals, Inc.

​

Amphastar is... (truncated) More information and resources are available at www.amphastar.com.

​

Amphastar’s logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.

​

Forward Looking Statements

​

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar’s historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to

​

​ reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

​

Contact Information:

​

Amphastar Pharmaceuticals, Inc.

Bill Peters

Chief Financial Officer

(909) 476-3416

​

​

Table I

Amphastar Pharmaceuticals, Inc.

Condensed Consolidated Statement of Operations

(Unaudited; in thousands, except per share data)

​

​

​

​

Table II

Amphastar Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

​

​

​

​

Table III

Amphastar Pharmaceuticals, Inc.

Reconciliation of Non-GAAP Measures

(Unaudited; in thousands, except per share data)

​

​

​

​

​

## Financial statements

### Income Statement (Three Months Ended (in thousands))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 |
|---|---:|---:|
| Net revenues | 171,171 | 170,528 |
| GAAP net income | 6,420 | 25,285 |
| Adjusted non-GAAP net income* | 19,478 | 36,871 |
| GAAP diluted EPS | 0.14 | 0.51 |
| Adjusted non-GAAP diluted EPS* | 0.42 | 0.74 |

### Income Statement (Three Months Ended — First Quarter Results (in thousands))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Change – Dollars | Change – % |
|---|---:|---:|---:|---:|
| Net revenues: | BAQSIMI® | 32,434 | 38,355 | -5,921 | -15.0% |
| Net revenues: | Primatene MIST® | 29,763 | 29,051 | 712 | 2.0% |
| Net revenues: | Epinephrine | 19,213 | 18,587 | 626 | 3.0% |
| Net revenues: | Lidocaine | 13,460 | 13,644 | -184 | -1.0% |
| Net revenues: | Glucagon | 9,170 | 20,843 | -11,673 | -56.0% |
| Net revenues: | Other products | 67,131 | 50,048 | 17,083 | 34.0% |
| Net revenues: | Total net revenues | 171,171 | 170,528 | 643 | 0.0% |

### Income Statement (Three Months Ended — Changes in net revenues as compared to the first quarter of the prior year were primarily driven by: (in thousands))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Change – Dollars | Change – % |
|---|---:|---:|---:|---:|
| Net revenues | 171,171 | 170,528 | 643 | 0.0% |
| Cost of revenues | 100,849 | 85,277 | 15,572 | 18.0% |
| Gross profit | 70,322 | 85,251 | -14,929 | -18.0% |
| as % of net revenues | 41.1% | 50.0% |  |  |

### Income Statement (Three Months Ended — Changes in the cost of revenues and gross margin were primarily driven by: (in thousands))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Change – Dollars | Change – % |
|---|---:|---:|---:|---:|
| Non-operating expenses: | Interest income | 2,400 | 2,089 | 311 | 15.0% |
| Non-operating expenses: | Interest expense | -6,553 | -6,286 | -267 | 4.0% |
| Non-operating expenses: | Other income (expenses), net | 575 | -2,234 | 2,809 | -126.0% |
| Non-operating expenses: | Total non-operating expenses, net | -3,578 | -6,431 | 2,853 | -44.0% |

### Income Statement (Three Months Ended — (Unaudited; in thousands, except per share data))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 |
|---|---:|---:|
| Net revenues | 171,171 | 170,528 |
| Cost of revenues | 100,849 | 85,277 |
| Gross profit | 70,322 | 85,251 |
| Operating expenses: | Selling, distribution, and marketing | 11,927 | 11,866 |
| Operating expenses: | General and administrative | 18,028 | 15,996 |
| Operating expenses: | Research and development | 26,737 | 20,096 |
| Operating expenses: | Total operating expenses | 56,692 | 47,958 |
| Operating expenses: | Income from operations | 13,630 | 37,293 |
| Non-operating expenses: | Interest income | 2,400 | 2,089 |
| Non-operating expenses: | Interest expense | -6,553 | -6,286 |
| Non-operating expenses: | Other income (expenses), net | 575 | -2,234 |
| Non-operating expenses: | Total non-operating expenses, net | -3,578 | -6,431 |
| Non-operating expenses: | Income before income taxes | 10,052 | 30,862 |
| Non-operating expenses: | Income tax provision | 3,632 | 5,577 |
| Non-operating expenses: | Net income | 6,420 | 25,285 |
| Net income per share: | Basic | 0.14 | 0.53 |
| Net income per share: | Diluted | 0.14 | 0.51 |
| Weighted-average shares used to compute net income per share: | Basic | 45,322 | 47,641 |
| Weighted-average shares used to compute net income per share: | Diluted | 46,458 | 49,890 |

### Income Statement (Three Months Ended March 31, 2026 — (Unaudited; in thousands, except per share data))

| | Three Months Ended March 31, 2026 – Cost of – revenue | Three Months Ended March 31, 2026 – Selling, – distribution – and marketing | Three Months Ended March 31, 2026 – General – and – administrative | Three Months Ended March 31, 2026 – Research – and – development | Three Months Ended March 31, 2026 – Income – tax provision |
|---|---:|---:|---:|---:|---:|
| GAAP | 100,849 | 11,927 | 18,028 | 26,737 | 3,632 |
| Intangible asset amortization | -6,250 |  | -1 | -19 |  |
| Share-based compensation | -2,456 | -360 | -5,137 | -1,321 |  |
| Litigation provision |  |  | -1,000 |  |  |
| Income tax provision on pre-tax adjustments |  |  |  |  | 3,486 |
| Non-GAAP | 92,143 | 11,567 | 11,890 | 25,397 | 7,118 |

### Income Statement (Three Months Ended March 31, 2025 — (Unaudited; in thousands, except per share data))

| | Three Months Ended March 31, 2025 – Cost of – revenue | Three Months Ended March 31, 2025 – Selling, – distribution – and marketing | Three Months Ended March 31, 2025 – General – and – administrative | Three Months Ended March 31, 2025 – Research – and – development | Three Months Ended March 31, 2025 – Income – tax provision |
|---|---:|---:|---:|---:|---:|
| GAAP | 85,277 | 11,866 | 15,996 | 20,096 | 5,577 |
| Intangible asset amortization | -6,220 |  | -1 | -19 |  |
| Share-based compensation | -2,338 | -313 | -4,569 | -1,173 |  |
| Income tax provision on pre-tax adjustments |  |  |  |  | 3,047 |
| Non-GAAP | 76,719 | 11,553 | 11,426 | 18,904 | 8,624 |

### Balance Sheet (December 31, — (in thousands, except per share data))

| | March 31, – 2026 – (unaudited) | December 31, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 170,939 | 170,177 |
| Current assets: | Restricted cash | 235 | 235 |
| Current assets: | Short-term investments | 121,012 | 112,635 |
| Current assets: | Restricted short-term investments | 2,200 | 2,200 |
| Current assets: | Accounts receivable, net | 147,848 | 143,560 |
| Current assets: | Inventories | 170,194 | 176,890 |
| Current assets: | Income tax refunds and deposits | 9,605 | 17,167 |
| Current assets: | Prepaid expenses and other assets | 11,650 | 13,152 |
| Current assets: | Total current assets | 633,683 | 636,016 |
| Current assets: | Property, plant, and equipment, net | 307,231 | 310,567 |
| Current assets: | Finance lease right-of-use assets | 185 | 221 |
| Current assets: | Operating lease right-of-use assets | 71,496 | 42,931 |
| Current assets: | Goodwill and intangible assets, net | 559,623 | 565,965 |
| Current assets: | Other assets | 33,480 | 31,135 |
| Current assets: | Deferred tax assets | 42,464 | 42,464 |
| Current assets: | Total assets | 1,648,162 | 1,629,299 |
